Skip to main content


Thinking outside the box: Strategies to combat staff shortages
Hear strategies for how community-based oncology practices can combat the pervasive staff shortage by increasing efficiency and reducing staff burnout. Read More ›

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib. Read More ›

Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting. Read More ›

INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study. Read More ›

Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer. Read More ›

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study. Read More ›

New Developments on Prognostic Markers for Patients With Early Breast Cancer
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials. Read More ›

Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study. Read More ›

Sanjay Juneja, MD, on the Approval of ORSERDU™
Dr Sanjay Juneja, medical oncologist and hematologist, and Chief of Oncology at Baton Rouge General Hospital–Mary Bird Perkins Cancer Center in Baton Rouge, LA, also known as “The Onc Doc,” is a well-known healthcare influencer. In the video above, Dr Juneja provides his perspectives on key efficacy and safety data from the EMERALD trial, the importance of testing for ESR1 mutations, and what the approval of ORSERDU (elacestrant) means for patients. Read More ›

Virtual Clinical Utility Study to Assess Use of a Novel Biomarker in Treatment Decision-Making
Welcome to this virtual clinical utility study. It's being done to assess use of a novel biomarker in the treatment decision-making for immunotherapy-eligible first-line advanced stage non-small cell lung cancer patients. Read More ›

Page 1 of 16